Seres Therapeutics Financials
MCRB Stock | USD 0.78 0.03 4.00% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 1.69 | 1.7779 |
|
|
The financial analysis of Seres Therapeutics is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Seres Therapeutics includes many different criteria found on its balance sheet. For example, investors should never minimize Seres Therapeutics' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Seres Therapeutics' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Seres Therapeutics.
Net Income |
|
With this module, you can analyze Seres financials for your investing period. You should be able to track the changes in Seres Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Seres | Select Account or Indicator |
Understanding current and past Seres Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Seres Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Seres Therapeutics' assets may result in an increase in income on the income statement.
Evaluating Seres Therapeutics' financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of Seres Therapeutics' profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the Seres Therapeutics' relative financial performance
Chance Of Distress
Over 73
100 | Zero |
High
Seres Therapeutics has more than 73 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Seres Therapeutics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, Seres Therapeutics' odds of distress score SHOULD NOT be confused with the real chance of Seres Therapeutics filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as Seres is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include Seres Therapeutics' liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More InfoThe data published in Seres Therapeutics' official financial statements usually reflect Seres Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Seres Therapeutics. For example, before you start analyzing numbers published by Seres accountants, it's critical to develop an understanding of what Seres Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Seres Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Seres Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Seres Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Seres Therapeutics. Please utilize our Beneish M Score to check the likelihood of Seres Therapeutics' management manipulating its earnings.
Seres Therapeutics Company Summary
Seres Therapeutics competes with Aegean Airlines, Virco Manufacturing, Acco Brands, Global Crossing, and Azul SA. Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Seres Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 333 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
CIK Number | 0001609809 |
ISIN | US81750R1023 |
CUSIP | 81750R102 |
Region | North America |
Location | Massachusetts; U.S.A |
Business Address | 101 Cambridgepark Drive, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | NYSE Composite |
Website | www.serestherapeutics.com |
Phone | 617 945 9626 |
Currency | USD - US Dollar |
You should never invest in Seres Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Seres Stock, because this is throwing your money away. Analyzing the key information contained in Seres Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Seres Therapeutics Key Financial Ratios
Generally speaking, Seres Therapeutics' financial ratios allow both analysts and investors to convert raw data from Seres Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Seres Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Seres Therapeutics reports annually and quarterly.Return On Equity | -5.39 | ||||
Price To Sales | 0.94 X | ||||
Gross Profit | (165.79 M) |
Seres Therapeutics Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 132.4M | 342.9M | 354.9M | 348.8M | 358.6M | 225.8M | |
Other Current Liab | 10.9M | 14.2M | 45.1M | 59.8M | 80.6M | 84.6M | |
Net Debt | (20.3M) | (75.3M) | (130.8M) | (440K) | 86.0M | 90.3M | |
Retained Earnings | (459.6M) | (548.8M) | (614.4M) | (864.5M) | (978.2M) | (929.3M) | |
Accounts Payable | 4.9M | 4.0M | 13.7M | 17.4M | 3.6M | 6.7M | |
Cash | 65.1M | 116.0M | 180.0M | 163.0M | 128.0M | 93.9M | |
Other Current Assets | 33.3M | 5.8M | 12.9M | 13.4M | 9.1M | 8.6M | |
Total Liab | 180.8M | 168.2M | 223.4M | 338.0M | 403.5M | 423.6M | |
Total Current Assets | 100.2M | 268.8M | 303.6M | 194.8M | 175.4M | 166.7M | |
Common Stock | 70K | 91K | 92K | 125K | 135K | 141.8K | |
Other Liab | 94.4M | 86.6M | 98.5M | 93.9M | 108.0M | 78.0M | |
Short Term Debt | 4.5M | 5.6M | 6.6M | 4.1M | 6.7M | 6.4M | |
Net Tangible Assets | (48.3M) | 174.8M | 131.5M | 10.8M | 9.7M | 9.2M | |
Capital Surpluse | 411.3M | 723.5M | 745.8M | 875.2M | 1.0B | 552.2M |
Seres Therapeutics Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Seres Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 502K | 2.9M | 2.9M | 6.0M | 13.2M | 13.8M | |
Operating Income | (71.9M) | (88.1M) | (64.5M) | (246.5M) | (107.3M) | (112.6M) | |
Ebit | (71.9M) | (88.1M) | (64.5M) | (246.5M) | (107.3M) | (112.6M) | |
Research Development | 80.1M | 90.6M | 141.9M | 172.9M | 145.9M | 87.5M | |
Ebitda | (68.3M) | (86.2M) | (62.7M) | (244.1M) | (92.2M) | (96.8M) | |
Income Before Tax | (70.3M) | (89.1M) | (65.6M) | (250.2M) | (113.7M) | (119.4M) | |
Net Income | (64.2M) | (86.5M) | (61.5M) | (253.8M) | (113.7M) | (119.4M) | |
Income Tax Expense | (6.0M) | (2.7M) | (4.1M) | 3.7M | 3.3M | 3.5M | |
Total Revenue | 34.5M | 33.2M | 144.9M | 7.1M | 126.3M | 132.6M | |
Gross Profit | (45.6M) | (57.4M) | 143.2M | 6.1M | 111.2M | 116.8M | |
Cost Of Revenue | 80.1M | 90.6M | 1.7M | 1.0M | 15.1M | 14.4M | |
Interest Income | 1.0M | 946K | 2.9M | 3.1M | 6.7M | 7.1M | |
Net Interest Income | 531K | (2.0M) | (40K) | (3.0M) | (4.3M) | (4.1M) |
Seres Therapeutics Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Seres Therapeutics. It measures of how well Seres is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Seres Therapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Seres had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Seres Therapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | (20.8M) | 50.9M | 72.0M | (16.8M) | (35.1M) | (33.3M) | |
Free Cash Flow | (77.5M) | (94.2M) | (2.9M) | (238.6M) | (125.3M) | (119.1M) | |
Depreciation | 7.6M | 6.6M | 5.9M | 6.6M | 15.1M | 15.9M | |
Other Non Cash Items | 2.3M | 3.3M | 2.0M | 7.6M | 120.4M | 126.4M | |
Capital Expenditures | 1.0M | 591K | 9.6M | 9.8M | 8.0M | 5.8M | |
Net Income | (70.3M) | (89.1M) | (65.6M) | (250.2M) | (113.7M) | (119.4M) | |
End Period Cash Flow | 65.1M | 116.0M | 188.0M | 171.2M | 128.0M | 95.4M | |
Investments | (29.5M) | (158.3M) | 73.7M | 92.2M | 17.4M | 18.3M | |
Change To Netincome | 8.7M | 8.8M | 24.3M | 25.5M | 29.3M | 16.2M |
Seres Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Seres Therapeutics's current stock value. Our valuation model uses many indicators to compare Seres Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Seres Therapeutics competition to find correlations between indicators driving Seres Therapeutics's intrinsic value. More Info.Seres Therapeutics is considered to be number one stock in price to sales category among related companies. It is considered to be number one stock in beta category among related companies totaling about 2.41 of Beta per Price To Sales. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Seres Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Seres Therapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Seres Therapeutics' earnings, one of the primary drivers of an investment's value.Seres Therapeutics Systematic Risk
Seres Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Seres Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Seres Therapeutics correlated with the market. If Beta is less than 0 Seres Therapeutics generally moves in the opposite direction as compared to the market. If Seres Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Seres Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Seres Therapeutics is generally in the same direction as the market. If Beta > 1 Seres Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
About Seres Therapeutics Financials
What exactly are Seres Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Seres Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Seres Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Seres Therapeutics investors may use each financial statement separately, they are all related. The changes in Seres Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Seres Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Seres Therapeutics Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Seres Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Seres has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Seres Therapeutics' financials are consistent with your investment objective using the following steps:- Review Seres Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Seres Therapeutics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Seres Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Seres Therapeutics' stock is overvalued or undervalued.
Seres Therapeutics Thematic Clasifications
Seres Therapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Pharmaceutical Products | View |
Today, most investors in Seres Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Seres Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Seres Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Seres Therapeutics March 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Seres Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Seres Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Seres Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Seres Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Seres Therapeutics's daily price indicators and compare them against related drivers.
Information Ratio | (0.09) | |||
Maximum Drawdown | 29.8 | |||
Value At Risk | (8.33) | |||
Potential Upside | 8.7 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Seres Stock analysis
When running Seres Therapeutics' price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is Seres Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.89) | Revenue Per Share 0.987 | Quarterly Revenue Growth (0.93) | Return On Assets (0.19) | Return On Equity (5.39) |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.